Federal Circuit Clarifies Written Description and Enablement Standards for Method-of-Treatment Patent Claims Using a Well-Known Antibody Genus

Why It Matters

The decision clarifies that patent protection can extend to treatment methods employing known antibody families, potentially expanding the enforceable scope of biotech patents. Companies can now rely on well‑characterized biologic genera to defend MOT claims against written‑description and enablement attacks.

Key Takeaways

• Federal Circuit upheld MOT claims using a well‑known antibody genus.
• Court distinguished Amgen by treating genus as separate from composition claim.
• Written‑description satisfied because genus and humanization were routine.
• Enablement met; no undue experimentation required to identify effective antibodies.
• Decision may broaden validity of MOT patents relying on known antibody classes.

Pulse Analysis

The Federal Circuit’s ruling in Teva v. Eli Lilly revisits the long‑standing tension between § 112’s written‑description and enablement standards and the rapid evolution of biologic therapeutics. By carving out a distinction between method‑of‑treatment (MOT) claims that merely invoke a known antibody genus and composition‑of‑matter claims that claim the genus itself, the court sidestepped the Amgen precedent that tightened written‑description scrutiny for biologics. This nuanced approach acknowledges that the inventive step often lies in the therapeutic application rather than the molecular scaffold, especially when the scaffold is already entrenched in the literature.

In its analysis, the panel leaned on prior decisions such as Ajinomoto and Herschler, which upheld claims that leveraged well‑known chemical or biological genera as tools for a separate invention. The court emphasized that Teva’s specification disclosed that all humanized anti‑CGRP antibodies would treat headache, removing any need for a burdensome “research assignment” to identify effective variants. Consequently, the enablement inquiry collapsed: routine humanization techniques and the undisputed class effect satisfied the statutory requirement without demanding exhaustive experimental validation.

The broader implication for the pharmaceutical industry is a clearer pathway to protect MOT patents that depend on established biologic families. Companies can now draft claims that reference a known antibody class while focusing on a novel therapeutic use, potentially extending patent life and strengthening enforcement positions. However, litigants must still ensure that the class effect is indisputable and that the specification makes the link between the genus and the therapeutic outcome explicit, lest courts revert to stricter Amgen‑style scrutiny.